# Natural products modulate programmed cell death signaling mechanism for treating endometriosis: a review

**Authors:** Zhen Zhao, Fangyuan Liu, Yang Yu, Ying Shen, Danni Ding, Fengjuan Han

PMC · DOI: 10.3389/fphar.2026.1742212 · Frontiers in Pharmacology · 2026-01-29

## TL;DR

This review explores how natural products can help treat endometriosis by influencing programmed cell death mechanisms.

## Contribution

The paper systematically reviews recent advances in using natural products to modulate PCD for endometriosis treatment.

## Key findings

- Dysregulation of programmed cell death is linked to endometriosis progression.
- Natural products show potential in modulating PCD pathways like apoptosis and autophagy.
- Key signaling pathways such as PI3K/Akt/mTOR and NF-κB are involved in PCD regulation in endometriosis.

## Abstract

Endometriosis (EMs) is a gynecological inflammatory disease that depends on estrogen. Its chief symptoms include dysmenorrhea, chronic pelvic pain, reduced fertility, and pelvic masses. Although various hormonal therapies and surgical treatments are available, their long-term effectiveness is limited, recurrence rates are high, and side effects are significant. Programmed cell death (PCD) is a genetically regulated mechanism of cell clearance that includes apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis. Numerous studies showed that dysregulation of PCD is strongly associated with the development of EMs, suggesting that targeting key molecular mechanisms of PCD could be a promising therapeutic strategy. Natural products, known for their multitarget activity and low toxicity, show unique advantages in modulating PCD in EMs. This review elucidates the regulatory mechanisms of various PCD pathways in EMs and their interactions with key signaling cascades, including PI3K/Akt/mTOR, MAPK, NF-κB, and Bcl-2. Furthermore, it explores how natural products modulate these PCD mechanisms and related pathways, providing insights into their therapeutic potential at the molecular level. We used “endometriosis,” “programmed cell death,” “natural products”, and “signaling pathway” as keywords to systematically search the PubMed, Web of Science, and CNKI databases for relevant literature published in the past 10 years. A total of 55 studies were included, highlighting recent advances in regulating EMs progression through PCD modulation by natural products. The goal of this review is to provide a theoretical foundation for improving current treatments for EMs and to offer practical recommendations for future research.

## Linked entities

- **Diseases:** endometriosis (MONDO:0005133)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}
- **Diseases:** EMs (MESH:D004715), pelvic masses (MESH:C536030), dysmenorrhea (MESH:D004412), toxicity (MESH:D064420), gynecological inflammatory disease (MESH:D005831), chronic pelvic pain (MESH:D011472)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12894019/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12894019/full.md

## References

118 references — full list in the complete paper: https://tomesphere.com/paper/PMC12894019/full.md

---
Source: https://tomesphere.com/paper/PMC12894019